TNF and systemic lupus erythematosus: Most of the patients with RA or SLE are on double therapy (methotrexate + antimalarials or antimalarial + azatioprine) or, in some extreme cases (3%), on rituximab and 1% on belimumab or 4% on TNF-alpha agents.